Associated Papers
Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signaling.
Krishna A et al.
Nature Genetics, 2026
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
CD73 restrains mutant β-catenin oncogenic activity in endometrial carcinomas.
Hirsch RM et al.
Jci Insight, 2026
Multi-omics profiling uncovers immune-molecular clusters with distinct chemo-immunotherapeutic vulnerabilities in a mouse model of triple-negative breast cancer.
Castellanet O et al.
Molecular Cancer, 2026
Expanding the Molecular Characterization of Adenoid Ameloblastoma by Assessing a Panel of Oncogenes and Tumor Suppressor Genes.
Fonseca YG et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2026
Lymphoid enhancer-binding factor 1 (LEF1) immunostaining as a surrogate for β-catenin (CTNNB1) mutations.
Hewer E et al.
Journal of Clinical Pathology, 2025
Nucleotide Substitution Biases in Related Cancer Driver Genes.
Khadre A et al.
International Journal of Molecular Sciences, 2025
Molecular analysis of the evolutionary history of endometrial and ovarian carcinoma in Lynch syndrome.
Kauppinen AK et al.
International Journal of Cancer, 2025
Enabling whole genome sequencing analysis from FFPE specimens in clinical oncology.
Domenico D et al.
Nature Communications, 2025
Adult granulosa cell tumours of the testis analogous to ovarian counterparts are exceptionally rare: analysis of a multicentric series and review of the literature.
Ricci C et al.
Histopathology, 2025
Somatic DICER1 pathogenic variants detected in a well-differentiated fetal lung adenocarcinoma diagnosed in a man with familial adenomatous polyposis.
Ahmed A et al.
Bjc Reports, 2025
Primary ovarian solid pseudopapillary neoplasm with CTNNB1 c.94G > T (p.D32Y) mutation: a case report.
Xu M et al.
International Journal of Surgery Case Reports, 2025
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis.
Salani F et al.
Esmo Open, 2025
Mutational scanning reveals substrate-assisted autoregulation of the WNT destruction complex.
Padmanarayana M et al.
Biorxiv : the Preprint Server for Biology, 2025
Comprehensive molecular characterization of craniopharyngiomas using whole transcriptome and spatial transcriptomics approaches.
Kert Š et al.
Brain Tumor Pathology, 2025
A structurally informed human protein-protein interactome reveals proteome-wide perturbations caused by disease mutations.
Xiong D et al.
Nature Biotechnology, 2025
Leveraging sequences missing from the human genome to diagnose cancer.
Georgakopoulos-Soares I et al.
Communications Medicine, 2025
MutationAssessor in cBioPortal.
Su Y et al.
Biorxiv : the Preprint Server for Biology, 2025
Novel CTNNB1 gene mutations reveal critical pathogenic mechanisms in pediatric hepatoblastoma.
Kumar S et al.
Pediatric Surgery International, 2025
Patient-derived organoids inform pharmacogenomic vulnerabilities in liver cancer.
Wong AM et al.
Jhep Reports : Innovation in Hepatology, 2025
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
Prostate Ductal Adenocarcinoma Revisited: Clinicopathological and Genomic Characterization Identifies Heterogenous Group of Diseases with Implications for Patient Management.
Cai Q et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States.
George SL et al.
Cancer Discovery, 2025
[Next generation sequencing (NGS)-based molecular panel analysis for metastatic prostate cancer: how often can we detect druggable mutations? : NGS for metastatic adenocarcinoma of the prostate].
Steenbock O et al.
Urologie (heidelberg, Germany), 2025
Unveiling immunogenic characteristics and neoantigens in endometrial cancer with POLE hotspot mutations for improved immunotherapy.
Huang J et al.
Frontiers in Immunology, 2025
The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs).
Zhang L et al.
Elife, 2024
CD73 restrains mutant β-catenin oncogenic activity in endometrial carcinomas.
Hirsch RM et al.
Biorxiv : the Preprint Server for Biology, 2024
Factor analysis and subtyping significance of CTNNB1 gene mutation detection in adamantinomatous craniopharyngioma.
Zhang H et al.
Genes & Diseases, 2024
Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression.
Apps JR et al.
Acta Neuropathologica Communications, 2024
β-Catenin alterations in testicular Leydig cell tumour: a immunohistochemical and molecular analysis.
Kitagawa Y et al.
Histopathology, 2024
Desmoplastic fibroma of the pediatric cranium with CTNNB1 mutation: case report and literature review.
Wang X et al.
Child's Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery, 2024
Molecular profiling of primary endometrioid endometrial cancer and matched lung metastases: CTNNB1 mutation as a potential driver.
Gordhandas S et al.
Gynecologic Oncology Reports, 2024
Primary Solid Pseudopapillary Tumor of the Ovary: A Case Report and Review of the Literature.
Lee J et al.
Journal of Clinical Medicine, 2024
Molecular and pathologic data to guide selection of patients with endometrioid endometrial cancer for ovarian preservation.
Manning-Geist BL et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, 2024
Superficial fibromas with CTNNB1 mutation.
Kuntze A et al.
Genes, Chromosomes & Cancer, 2024
Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy response.
Hu Z et al.
Nature Genetics, 2024